AGER and atherosclerosis: This is the first study, to our knowledge, to demonstrate that inhibition of RAGE activation by administration of the RAGE decoy receptor, sRAGE, results in a significant, dose-dependent decrease in angiotensin II induced atherosclerosis formation and improvement in 60 day survival.